2024/2653(DEA)
Examination of variations to the terms of marketing authorisations for medicinal products for human use
Basic information
2024/2653(DEA)
DEA - Delegated acts procedure
Subject
4.20.01 Medicine, diseases
4.20.04 Pharmaceutical products and industry
Status
Procedure completed - delegated act enters into force
Key players
-
European Parliament
Committee responsible Rapporteur Appointed
Key events
| Date | Event | Reference | Summary |
|---|---|---|---|
| 11/03/2024 | Non-legislative basic document published | C(2024)01627 | |
| 11/03/2024 | Initial period for examining delegated act 3.0 month(s) | ||
| 13/03/2024 | Committee referral announced in Parliament | ||
| 19/06/2024 | Delegated act not objected by Parliament |
Technical information
| Procedure reference | 2024/2653(DEA) |
|---|---|
| Procedure type | DEA - Delegated acts procedure |
| Procedure subtype | Examination of delegated act |
| Stage reached in procedure | Procedure completed - delegated act enters into force |
| Committee dossier |
ENVI/9/15028
|
Documentation gateway
-
Document type Reference Date Summary Non-legislative basic document C(2024)01627 11/03/2024 Document attached to the procedure SWD(2024)0058 11/03/2024